Latest Industry Projects

Janssen, Johnson and Johnson Innovation, Announce Collaboration with Belgian Scientists

Janssen Research & Development, Division of Janssen Pharmaceutica NV, and Johnson & Johnson Innovation announced the launch of a collaborative initiative with scientists from three prominent Belgian academic institutions and research centers to drive discoveries to improve the prevention, diagnosis and treatment of neurodegenerative diseases. Janssen Research & Development and Johnson & Johnson Innovation are committing up to 5 million Euros for this project over a five-year period. The project seeks to attract top researchers in the Benelux scientific community to submit proposals for cutting-edge research in neurodegenerative disorders. Janssen Research & Development will collaborate initially with KU Leuven, University Hospitals Leuven and VIB (Vlaams Instituut voor Biotechnologie) to create opportunities for collaborative research, and will invite other academic institutions to join the project as its next phase begins later this year. This effort advances the Janssen and Johnson & Johnson Healthy Minds initiative, which strives to accelerate progress in the fight against neurologic and brain disorders and to build on the companies’ longstanding commitment to neuroscience and mental health. The aim of the initiative is to gain deeper insight into these diseases and accelerate delivery of breakthrough options to prevent, diagnose and treat them, ultimately helping patients to live better lives. A ceremony to celebrate the launch of the initiative is planned for May 29 at Arenberg Castle in Heverlee, Belgium. Dr. Mark Waer, rector of the KU Leuven and his successor, Professor Rik Torfs, as well as representatives from the Belgian government, will participate in the event at Arenberg Castle. Project Name research centers for prevention, diagnosis and treatment of neurodegenerative diseases Location Belgium Commence 2013 Completion 2018 Estimated Investment EUR 5 million Capacity -NA- Key Players Janssen Pharmaceutica NV, and Johnson & Johnson Innovation

Other Projects